[Iodine-125 interstitial brachytherapy for malignant tumor]

Area of Science:

• Oncology
• Radiotherapy
• Surgical Oncology

Context:

• Malignant tumors pose a significant global health challenge.
• Effective treatment strategies are crucial for improving patient survival and quality of life.
• Radical resection combined with adjuvant therapies is a standard approach for managing advanced-stage cancers.

Purpose:

• To evaluate the clinical efficacy and safety of Iodine-125 ((125)I) interstitial brachytherapy in patients with malignant tumors.
• To assess the impact of (125)I brachytherapy on tumor recurrence and metastasis.
• To monitor relevant clinical and immunological markers post-treatment.

Summary:

• This study involved 112 patients with stage II and III malignant tumors who underwent radical resection followed by intraoperative (125)I implantation.
• Post-operative monitoring included white blood cell counts, immune markers, blood biochemistry, ultrasonography, and X-rays to track tumor recurrence and metastasis.
• The treatment demonstrated a low mortality rate, with only 3 deaths due to recurrence within six months, and long-term survival observed up to 35 months in the remaining patients.

Impact:

• Iodine-125 ((125)I) interstitial brachytherapy presents a simple, safe, and effective therapeutic option for malignant tumors.
• The combined approach of surgery and (125)I brachytherapy shows promise in reducing tumor recurrence and improving survival rates.
• This study contributes valuable data on the clinical utility of (125)I brachytherapy in managing advanced-stage cancers.